Uliledlimab

Monoclonal antibody

TTJ Biopharma Co., Ltd.

Uliledlimab is one of 35 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

PORTRAZZA

Eli Lilly

Preclinical

8 2

Lenvima

Eisai

Preclinical

6 3

Ofev

Boehringer Ingelheim

Preclinical

7 4

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 5

REGN2810

Regeneron

Preclinical

1 6

Vidaza

Bristol-Myers Squibb

Preclinical

1 7

Treatment

GSK

Preclinical

1 8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—9

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Preclinical

3 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2/3Active, not recruiting

Non-Small Cell Lung Cancer

NCT06984588

Q1 2029

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer

NCT07005336

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Active, not recruiting·TTJ Biopharma Co., Ltd.·Phase 2·NCT07005336·150 enrolled

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Active, not recruiting·TTJ Biopharma Co., Ltd.·Phase 2/3·NCT06984588·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Uliledlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Uliledlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Uliledlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TJ Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Company: TTJ Biopharma Co., Ltd.

Uliledlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

References

Drug Info

Quick Facts

Related News